drug carriers

Summary

Summary: Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.

Top Publications

  1. ncbi Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier, 73 20, 1200 Brussels, Belgium
    J Control Release 133:11-7. 2009
  2. ncbi Nanocarriers as an emerging platform for cancer therapy
    Dan Peer
    Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Nanotechnol 2:751-60. 2007
  3. ncbi Drug delivery systems: entering the mainstream
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton T6G 2H7, Canada
    Science 303:1818-22. 2004
  4. ncbi Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies
    Farnaz Esmaeili
    Novel Drug Delivery Systems Laboratory, Faculty of Pharmacy, Department of Pharmaceutics, Tehran University of Medical Sciences, PO Box 14155 6451, Tehran, Iran
    J Pharm Sci 98:2718-30. 2009
  5. ncbi Impact of nanotechnology on drug delivery
    Omid C Farokhzad
    Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    ACS Nano 3:16-20. 2009
  6. ncbi Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
    Matthew R Dreher
    Department of Biomedical Engineering, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:335-44. 2006
  7. pmc Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers
    - Wahajuddin
    Pharmacokinetics and Metabolism Division, CSIR Central Drug Research Institute, Lucknow, Uttar Pradesh, India
    Int J Nanomedicine 7:3445-71. 2012
  8. ncbi Albumin-based nanoparticles as potential controlled release drug delivery systems
    Ahmed O Elzoghby
    Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, El Khartoum Square, Azarita, Alexandria 21521, Egypt
    J Control Release 157:168-82. 2012
  9. ncbi Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
    Donald E Owens
    Department of Chemical Engineering, University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA
    Int J Pharm 307:93-102. 2006
  10. ncbi Endosomal escape pathways for delivery of biologicals
    Amir K Varkouhi
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, University of Utrecht, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    J Control Release 151:220-8. 2011

Detail Information

Publications402 found, 100 shown here

  1. ncbi Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier, 73 20, 1200 Brussels, Belgium
    J Control Release 133:11-7. 2009
    ..Therefore, PTX-loaded nanoparticles may be considered as an effective anticancer drug delivery system for cancer chemotherapy...
  2. ncbi Nanocarriers as an emerging platform for cancer therapy
    Dan Peer
    Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Nanotechnol 2:751-60. 2007
    ..We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment...
  3. ncbi Drug delivery systems: entering the mainstream
    Theresa M Allen
    Department of Pharmacology, University of Alberta, Edmonton T6G 2H7, Canada
    Science 303:1818-22. 2004
    ..Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics...
  4. ncbi Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies
    Farnaz Esmaeili
    Novel Drug Delivery Systems Laboratory, Faculty of Pharmacy, Department of Pharmaceutics, Tehran University of Medical Sciences, PO Box 14155 6451, Tehran, Iran
    J Pharm Sci 98:2718-30. 2009
    ..4 +/- 1.75 nM. Conjugation also maintained DTX plasma level at 16.19% up to 2 h after injection compared with 2.51% for Taxotere, hence increasing the chance of nanoparticles uptake by tumor cells...
  5. ncbi Impact of nanotechnology on drug delivery
    Omid C Farokhzad
    Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    ACS Nano 3:16-20. 2009
    ..Herein, we focus on the application of nanotechnology to drug delivery and highlight several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics...
  6. ncbi Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
    Matthew R Dreher
    Department of Biomedical Engineering, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:335-44. 2006
    Delivery of anticancer therapeutic agents to solid tumors is problematic. Macromolecular drug carriers are an attractive alternative drug delivery method because they appear to target tumors and have limited toxicity in normal tissues...
  7. pmc Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers
    - Wahajuddin
    Pharmacokinetics and Metabolism Division, CSIR Central Drug Research Institute, Lucknow, Uttar Pradesh, India
    Int J Nanomedicine 7:3445-71. 2012
    ....
  8. ncbi Albumin-based nanoparticles as potential controlled release drug delivery systems
    Ahmed O Elzoghby
    Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, El Khartoum Square, Azarita, Alexandria 21521, Egypt
    J Control Release 157:168-82. 2012
    ..Nanocomplexes of albumin with other components in the area of drug delivery are also included in this review...
  9. ncbi Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
    Donald E Owens
    Department of Chemical Engineering, University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA
    Int J Pharm 307:93-102. 2006
    ..This method creates a hydrophilic protective layer around the nanoparticles that is able to repel the absorption of opsonin proteins via steric repulsion forces, thereby blocking and delaying the first step in the opsonization process...
  10. ncbi Endosomal escape pathways for delivery of biologicals
    Amir K Varkouhi
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, University of Utrecht, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    J Control Release 151:220-8. 2011
    ..In this review, several mechanisms and agents which are involved in endosomal escape are introduced...
  11. pmc Targeting of drugs and nanoparticles to tumors
    Erkki Ruoslahti
    Vascular Mapping Center, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
    J Cell Biol 188:759-68. 2010
    ..We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle...
  12. ncbi Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers
    Igor I Slowing
    Department of Chemistry and US Department of Energy Ames Laboratory, Iowa State University, Ames, Iowa 50011 3111, USA
    Adv Drug Deliv Rev 60:1278-88. 2008
    ..We envision that these MSN-based systems have a great potential for a variety of drug delivery applications, such as the site-specific delivery and intracellular controlled release of drugs, genes, and other therapeutic agents...
  13. ncbi PEGylation, successful approach to drug delivery
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Italy
    Drug Discov Today 10:1451-8. 2005
    ..Thanks to these favorable properties, PEGylation now plays an important role in drug delivery, enhancing the potentials of peptides and proteins as therapeutic agents...
  14. ncbi Paclitaxel and its formulations
    Anil K Singla
    University Institute of Pharmaceutical Sciences, Panjab University, 160 014, Chandigarh, India
    Int J Pharm 235:179-92. 2002
    ..Various approaches employed so far include cosolvents, emulsions, micelles, liposomes, microspheres nanoparticles, cyclodextrins, pastes, and implants etc. which are discussed in this paper...
  15. ncbi Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
    H Maeda
    Laboratory of Microbiology and Oncology, Sojo University, Kumamoto, Japan
    Eur J Pharm Biopharm 71:409-19. 2009
    ....
  16. pmc Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
    Derek W Bartlett
    Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 210 41, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 104:15549-54. 2007
    ..Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics...
  17. ncbi To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
    Fabienne Danhier
    Universite Catholique de Louvain, Louvain Drug Research Institute, Unit of Pharmaceutics, UCL FARG 7320, avenue E Mounier, B 1200, Brussels, Belgium
    J Control Release 148:135-46. 2010
    ..Delivery of conventional chemotherapeutic anti-cancer drugs is mainly discussed...
  18. ncbi Micellar nanocarriers: pharmaceutical perspectives
    V P Torchilin
    Department of Pharmaceutical Sciences and Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Mugar Building, Room 312, 360 Huntington Avenue, Boston, Massachusetts 02115, USA
    Pharm Res 24:1-16. 2007
    ..used as pharmaceutical carriers for water-insoluble drugs and demonstrate a series of attractive properties as drug carriers. Among the micelle-forming compounds, amphiphilic copolymers, i.e...
  19. ncbi Long-circulating and target-specific nanoparticles: theory to practice
    S M Moghimi
    Molecular Targeting and Polymer Toxicology Group, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, United Kingdom
    Pharmacol Rev 53:283-318. 2001
    ..With regard to the targeting issues, attention is particularly focused on the importance of physiological barriers and disease states...
  20. ncbi Nanoparticle delivery of cancer drugs
    Andrew Z Wang
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    Annu Rev Med 63:185-98. 2012
    ..These drug carriers are passively targeted to tumors through the enhanced permeability and retention effect, so they are ideally ..
  21. pmc Shape effects of filaments versus spherical particles in flow and drug delivery
    Yan Geng
    NanoBioPolymers and Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Nanotechnol 2:249-55. 2007
    ..Although these findings show that long-circulating vehicles need not be nanospheres, they also lend insight into possible shape effects of natural filamentous viruses...
  22. pmc Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
    Samuel K Lai
    Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA
    Proc Natl Acad Sci U S A 104:1482-7. 2007
    ....
  23. ncbi Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles
    Kai Zhao
    College of Life Science, Heilongjiang University, Harbin, China
    Vaccine 29:8549-56. 2011
    ..These results laid a foundation for further development of DNA vaccines in nanoparticles before ultimate industrial application...
  24. ncbi Polymer-based nanocapsules for drug delivery
    C E Mora-Huertas
    Universite de Lyon, F 69622, Lyon, France
    Int J Pharm 385:113-42. 2010
    ..Consequently, the information obtained allows establishing criteria for selecting a method for preparation of nanocapsules according to its advantages, limitations and behaviours as a drug carrier...
  25. ncbi Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting
    Hu Lin Jiang
    Department of Agricultural Biotechnology, Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151 921, South Korea
    J Control Release 131:150-7. 2008
    ..v.) administration. Together, these results suggest that Gal-PEG-CHI-g-PEI, which has improved transfection efficiency and hepatocyte specificity both in vitro and in vivo, may be useful for gene therapy...
  26. ncbi Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives
    Katrin Knop
    Lehrstuhl für Organische und Makromolekulare Chemie IOMC, Friedrich Schiller University Jena, Humboldtstrasse 10, 07745 Jena, Germany
    Angew Chem Int Ed Engl 49:6288-308. 2010
    ..These possible side effects will be discussed in this Review and alternative polymers will be evaluated...
  27. ncbi Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins
    Igor I Slowing
    Department of Chemistry, U S DOE Ames Laboratory, Iowa State University, Ames, Iowa 50011 3111, USA
    J Am Chem Soc 129:8845-9. 2007
    ....
  28. ncbi Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
    Sanjeeb K Sahoo
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center 986025, Omaha, NE 68198 6025, USA
    J Control Release 82:105-14. 2002
    ..In conclusion, the residual PVA associated with nanoparticles is an important formulation parameter that can be used to modulate the pharmaceutical properties of PLGA nanoparticles...
  29. ncbi Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity
    Eva Maria Collnot
    Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrucken, Germany, Eastman Chemical Company
    Mol Pharm 4:465-74. 2007
    ..Hence, these results indicate that ATPase inhibition is an essential factor in the inhibitory mechanism of TPGS 1000 on cellular efflux pumps...
  30. pmc "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers
    R M Sawant
    Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, USA
    Bioconjug Chem 17:943-9. 2006
    ..We consider this result as the first step in the development of multifunctional stimuli-sensitive pharmaceutical nanocarriers...
  31. ncbi Functionalized carbon nanotubes for potential medicinal applications
    Yi Zhang
    School of Pharmaceutical Sciences, Shandong University, Jinan, 250100, China
    Drug Discov Today 15:428-35. 2010
    ..These potential applications are particularly encouraged by their ability to penetrate biological membranes and relatively low toxicity...
  32. ncbi Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier 73 20, 1200 Brussels, Belgium
    J Control Release 140:166-73. 2009
    ..Hence, the targeting of anti-cancer drug to tumor endothelium by RGD-labeled NP is a promising approach...
  33. ncbi Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery
    Fangqiong Tang
    Laboratory of Controllable Preparation and Application of Nanomaterials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, China
    Adv Mater 24:1504-34. 2012
    ..achievements in drug delivery using mesoporous silica nanoparticles and their multifunctional counterparts as drug carriers. In particular, the biological barriers for nano-based targeted cancer therapy and MSN-based targeting ..
  34. pmc Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems
    Josias H Hamman
    Department of Pharmaceutical Sciences, Tshwane University of Technology, Private Bag X680, Pretoria, 0001, South Africa
    Mar Drugs 8:1305-22. 2010
    ..Furthermore, recent investigations into the use of these complexes as excipients in drug delivery systems such as nano- and microparticles, beads, fibers, sponges and matrix type tablets are briefly described...
  35. ncbi Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
    H Cabral
    Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Hongo, Bunkyo ku, Japan
    Nat Nanotechnol 6:815-23. 2011
    ..We also showed that the penetration and efficacy of the larger micelles could be enhanced by using a transforming growth factor-β inhibitor to increase the permeability of the tumours...
  36. ncbi Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery
    Zhuang Liu
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    ACS Nano 1:50-6. 2007
    ..Such chemical partitioning should open up new opportunities in chemical, biological, and medical applications of novel nanomaterials...
  37. pmc Biodegradable luminescent porous silicon nanoparticles for in vivo applications
    Ji Ho Park
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, USA
    Nat Mater 8:331-6. 2009
    ..These results demonstrate a new type of multifunctional nanostructure with a low-toxicity degradation pathway for in vivo applications...
  38. ncbi Block copolymer micelles for drug delivery: design, characterization and biological significance
    K Kataoka
    Department of Materials Science, Graduate School of Engineering, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8656, Japan
    Adv Drug Deliv Rev 47:113-31. 2001
    ..As an important perspective on carrier systems based on polymeric micelles, their feasibility as non-viral gene vectors is also summarized in this review article...
  39. ncbi A review of stimuli-responsive nanocarriers for drug and gene delivery
    Srinivas Ganta
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 110 Mugar Life Sciences Building, Boston, MA 02115, United States
    J Control Release 126:187-204. 2008
    ....
  40. pmc Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic
    Anu Puri
    Center for Cancer Research Nanobiology Program, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    Crit Rev Ther Drug Carrier Syst 26:523-80. 2009
    ..Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade...
  41. ncbi Arginine functionalized peptide dendrimers as potential gene delivery vehicles
    Kui Luo
    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China
    Biomaterials 33:4917-27. 2012
    ..However, G6A with molecular weight of 46 kDa showed much higher cytotoxicity. The functionalized dendrimer G5A with optimal generation may be therefore a potential candidate for gene delivery vehicle...
  42. ncbi Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose
    Mengmeng Niu
    Key Laboratory of Smart Drug Delivery, School of Pharmacy, Fudan University, Shanghai, PR China
    Eur J Pharm Biopharm 81:265-72. 2012
    ..The hypoglycemic effect was size-dependent with the highest at 150 nm or 400 nm and was proportionally correlated to the administered dose. The results supported the hypothesis of insulin absorption as intact liposomes...
  43. pmc Nanocrystal technology, drug delivery and clinical applications
    Jens Uwe A H Junghanns
    Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, Berlin, Germany
    Int J Nanomedicine 3:295-309. 2008
    ..Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview...
  44. pmc Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs
    Tian Xia
    Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, USA
    ACS Nano 3:3273-86. 2009
    ..This novel use of a cationic MSNP extends its therapeutic use potential...
  45. ncbi Multifunctional nanocarriers
    Vladimir P Torchilin
    Department of Pharmaceutical Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Avenue, Boston, MA 02115, USA
    Adv Drug Deliv Rev 58:1532-55. 2006
    ....
  46. ncbi Large porous particles for pulmonary drug delivery
    D A Edwards
    Department of Chemical Engineering, Pennsylvania State University, 204 Fenske Laboratory, University Park, PA 16802, USA
    Science 276:1868-71. 1997
    ..High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles...
  47. pmc Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides
    Jingwei Li
    Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai 201203, People s Republic of China
    Biomaterials 32:4943-50. 2011
    ..In conclusion, the Pep TGN is a motif never been reported before and Pep TGN modified nanoparticles showed great potential in targeted drug delivery across the blood brain barrier...
  48. ncbi Mesoporous silica nanoparticles for intracellular controlled drug delivery
    Juan L Vivero-Escoto
    Department of Chemistry and U S Department of Energy, Ames Laboratory, Iowa State University, Ames, IA 50011 3111, USA
    Small 6:1952-67. 2010
    ..Finally, the latest breakthroughs for intracellular controlled drug release using stimuli-responsive mesoporous-silica-based systems are described...
  49. pmc Nanoparticle-based theranostic agents
    Jin Xie
    Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 2281, USA
    Adv Drug Deliv Rev 62:1064-79. 2010
    ..We will focus on construction strategies and will discuss the challenges and opportunities associated with this emerging technology...
  50. pmc Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors
    Beata Chertok
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109 1065, USA
    Biomaterials 29:487-96. 2008
    ..Hence, these nanoparticles appear to be a promising vehicle for glioma-targeted drug delivery...
  51. ncbi Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies
    Nina Dragicevic-Curic
    Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Lessingstrasse 8, 07743 Jena, Germany
    J Control Release 127:59-69. 2008
    ..05) of the drug in the SC compared to liposomes without terpenes and the ethanolic solution...
  52. ncbi Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics
    Anthony J Hickey
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box 7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599 7360, USA
    J Pharm Sci 96:1282-301. 2007
    ..This is the first of two papers that discuss static and dynamic methods of characterizing dry powder inhaler formulations...
  53. ncbi Locoregional cancer treatment with magnetic drug targeting
    C Alexiou
    Department of Otorhinolaryngology, Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany
    Cancer Res 60:6641-8. 2000
    ..Furthermore, it may be possible to use these magnetic particles as a "carrier system" for a variety of anticancer agents, e.g., radionuclides, cancer-specific antibodies, and genes...
  54. ncbi Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide
    Xiang Chen
    West China Hospital, Sichuan University, Chengdu, People s Republic of China
    J Control Release 145:17-25. 2010
    ..These results suggested that this FGFR-mediated drug delivery system may provide a new treatment strategy for tumors which overexpress FGFRs...
  55. ncbi Micellar nanocontainers distribute to defined cytoplasmic organelles
    Radoslav Savic
    Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, H3G 1Y6, Canada
    Science 300:615-8. 2003
    ..These micelles may thus be worth exploring for their potential to selectively deliver drugs to specified subcellular targets...
  56. pmc Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
    Samuel K Lai
    Department of Chemical and Biomolecular Engineering JH Primary Appointment, Johns Hopkins University, 3400 N Charles St, Baltimore, MD 21218, USA
    Adv Drug Deliv Rev 61:158-71. 2009
    ..It then reviews the design and development of new mucus-penetrating particles that may avoid rapid mucus clearance mechanisms, and thereby provide targeted or sustained drug delivery for localized therapies in mucosal tissues...
  57. ncbi The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel
    Chao Feng Mu
    College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
    Biomaterials 31:2371-9. 2010
    ....
  58. ncbi High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation
    Marc Lavertu
    Department of Chemical Engineering, Institute of Biomedical Engineering, Ecole Polytechnique of Montreal, P O Box 6079, Station Centre Ville, Montreal, Que, Canada H3C 3A7
    Biomaterials 27:4815-24. 2006
    ....
  59. pmc Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles
    Aaron F H Lum
    University of California Davis, Department of Biomedical Engineering, 451 East Health Sciences Drive, Davis, CA 95616, USA
    J Control Release 111:128-34. 2006
    ..This versatile method of delivery is shown to enable targeted deposition of nanoparticles in shear flow and could be modified to carry therapeutic agents for controlled release in targeted delivery applications...
  60. ncbi The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol
    K Teskac
    University of Ljubljana, Faculty of Pharmacy, Askerceva 7, Ljubljana, Slovenia
    Int J Pharm 390:61-9. 2010
    ..The cytostatic effect of SLN-RSV was much more expressed than that of RSV in solution. Delivery of RSV by SLN contributes to effectiveness of RSV on decreasing cell proliferation, with potential benefits for prevention of skin cancer...
  61. ncbi Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery
    Xintao Shuai
    Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    J Control Release 98:415-26. 2004
    ..Consistent with the in vitro release and CLSM results, a cytotoxicity study demonstrated that DOX-loaded micelles exhibited time-delayed cytotoxicity in human MCF-7 breast cancer cells...
  62. ncbi Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform
    Liangfang Zhang
    Department of Chemical Engineering, Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    ACS Nano 2:1696-702. 2008
    ..The NP is prepared by self-assembly through a single-step nanoprecipitation method in a reproducible and predictable manner, making it potentially suitable for scale-up...
  63. ncbi Advances in polymeric micelles for drug delivery and tumor targeting
    Uttam Kedar
    Bharati Vidyapeeth s College of Pharmacy, Mumbai, India
    Nanomedicine 6:714-29. 2010
    ..PMs have been used for the delivery of many anticancer agents in preclinical and clinical studies. This review summarizes recently available information regarding targeting of anticancer drugs to the tumor site using PMs...
  64. ncbi Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines
    Seyedeh Parinaz Akhlaghi
    Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    Nanomedicine 6:689-97. 2010
    ..The PTX-loaded nanoparticles showed cytotoxicity for NIH 3T3 and T47D breast carcinoma cells, along with no cytotoxicity for two colon cell lines (HT29, Caco2)...
  65. ncbi Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles
    Houli Li
    Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan, China
    J Control Release 133:238-44. 2009
    ..4%. The T(max) and MRT for quercetin in plasma were both delayed. Our studies provide evidence that SLNs are valuable as an oral delivery carrier to enhance the absorption of a poorly water soluble drug, quercetin...
  66. ncbi Targeting cancer cells: magnetic nanoparticles as drug carriers
    Christoph Alexiou
    Klinik und Poliklinik für Hals Nasen Ohren kranke, Universitat Erlangen Nurnberg, Erlangen, Germany
    Eur Biophys J 35:446-50. 2006
    ..In this letter we show that a strong magnetic field gradient at the tumour location accumulates the nanoparticles. Electron microscope investigations show that the ferrofluids can be enriched in tumour tissue and tumour cells...
  67. pmc Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line
    Huan Meng
    Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, USA
    ACS Nano 4:4539-50. 2010
    ..These results demonstrate that it is possible to use the MSNP platform to effectively deliver a siRNA that knocks down gene expression of a drug exporter that can be used to improve drug sensitivity to a chemotherapeutic agent...
  68. ncbi Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery
    Qin Tian
    Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, PR China
    Biomaterials 31:4748-56. 2010
    ..HCl (DOX.HCl) and the DOX-loaded CTS/PEG-GA nanoparticles were 47 and 79 ng/mL, respectively. Moreover, the DOX-loaded CTS/PEG-GA nanoparticles could effectively inhibit tumor growth in H22 cell-bearing mice...
  69. ncbi Polymer conjugates as anticancer nanomedicines
    Ruth Duncan
    Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK
    Nat Rev Cancer 6:688-701. 2006
    ..There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy...
  70. ncbi Iron oxide nanoparticles for sustained delivery of anticancer agents
    Tapan K Jain
    Department of Pharmaceutical Sciences, College of Pharmacy, Nebraska Medical Center, Omaha, Nebraska 68198 6025, USA
    Mol Pharm 2:194-205. 2005
    ..This nanoparticle formulation can be used as a universal drug carrier system for systemic administration of water-insoluble drugs while simultaneously allowing magnetic targeting and/or imaging...
  71. ncbi Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
    FASEB J 16:1217-26. 2002
    The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation...
  72. ncbi Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
    Petra Kocbek
    University of Ljubljana, Faculty of Pharmacy, Askerceva 7, Ljubljana, Slovenia
    J Control Release 120:18-26. 2007
    ..Furthermore, the results show the effectiveness of the new carrier system for targeted delivery of small or large active substances into cells or tissues of interest...
  73. ncbi Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody
    Donghua Liu
    School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Ji nan 250012, China
    Mol Pharm 8:2291-301. 2011
    ..These findings suggested that tNLC designed to bind specifically to VEGFR-2 can be used to deliver DTX to the tumor vasculature and tumor and may inhibit tumor growth...
  74. ncbi Folate-mediated delivery of macromolecular anticancer therapeutic agents
    Yingjuan Lu
    Department of Chemistry, 1393 Brown Building, Purdue University, West Lafayette, IN 47907, USA
    Adv Drug Deliv Rev 54:675-93. 2002
    ..This review presents a brief mechanistic background of folate-targeted macromolecular therapeutics and then summarizes the successes and failures observed with each major application of the technology...
  75. pmc Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process
    Min Soo Kim
    College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea
    Int J Nanomedicine 6:2997-3009. 2011
    ..The aim of this study was to improve the physicochemical properties and bioavailability of poorly water-soluble sirolimus via preparation of a solid dispersion of nanoparticles using a supercritical antisolvent (SAS) process...
  76. pmc Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery
    Surajit Das
    Institute of Chemical and Engineering Sciences, Agency for Science, Technology and Research, 1 Pesek Road, Jurong Island, Singapore, 627833, Republic of Singapore
    AAPS PharmSciTech 12:62-76. 2011
    Lipid nanoparticles based on solid matrix have emerged as potential drug carriers to improve gastrointestinal (GI) absorption and oral bioavailability of several drugs, especially lipophilic compounds...
  77. pmc Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells
    Moutushy Mitra
    Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Tamil Nadu, India
    Mol Vis 17:2724-37. 2011
    ....
  78. ncbi Gene therapy progress and prospects: nonviral vectors
    T Niidome
    Center for Pharmacogenetics, School of Pharmacy, 633 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Gene Ther 9:1647-52. 2002
    ..Improvement of delivery methods together with intelligent design of the DNA itself has brought about large degrees of enhancement in the efficiency, specificity and temporal control of nonviral vectors...
  79. ncbi Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery
    Alexander V Kabanov
    Department of Pharmaceutical Sciences, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198 6025, USA
    J Control Release 82:189-212. 2002
    ..These and other applications of Pluronic block copolymers in various drug delivery and gene delivery systems are considered...
  80. pmc Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer
    Ke Wang
    Cancer Institute Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China
    Int J Nanomedicine 6:3207-18. 2011
    ..A novel micelle formulation of oxaliplatin (OXA) encapsulated in chitosan vesicle was developed. The authors postulate that micelle encapsulation of OXA would eliminate both CSLCs and bulk cancer cells in colorectal cancer (CRC)...
  81. ncbi LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor
    Zhiqiang Yan
    Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, PR China
    J Control Release 157:118-25. 2012
    ..They are a safe and effective drug delivery system of antineoplastic agents for targeted therapy of lymphatic metastatic tumors...
  82. ncbi The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells
    Nuo Cao
    Center of Biomedical Engineering, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou 510275, China
    Biomaterials 32:2222-32. 2011
    ....
  83. pmc Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles
    Dongmei Zhao
    Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin, Heilongjiang, China
    Int J Nanomedicine 5:669-77. 2010
    ..3% and 27.2%, respectively. The amount of folate conjugation was 9.22 μg/mg of bovine serum albumin. The folate-decorated nanoparticles targeted a human prostate cancer cell line effectively...
  84. pmc Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations
    Parisa Yousefpour
    Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    Int J Nanomedicine 6:1487-96. 2011
    ..DOX-DS nanocomplexes may serve as a drug delivery system with efficient drug encapsulation and also may be taken into consideration in designing DOX controlled-release systems...
  85. ncbi Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier
    Wei Huang
    Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, China
    J Mater Sci Mater Med 22:853-63. 2011
    ..These results suggest that GA-functionalized micelles represent a promising carrier for drug delivery to the liver...
  86. pmc Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
    Johannes Lammer
    Cardiovascular and Interventional Radiology, Medical University Vienna, Vienna, Austria
    Cardiovasc Intervent Radiol 33:41-52. 2010
    ..001) and a significantly lower rate of doxorubicin-related side effects (P = 0.0001). TACE with DC Bead and doxorubicin is safe and effective in the treatment of HCC and offers a benefit to patients with more advanced disease...
  87. ncbi Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies
    Longzhang Zhu
    Life and Environment Science College, Shanghai Normal University, Shanghai 200234, PR China
    Colloids Surf B Biointerfaces 68:1-6. 2009
    ..The result showed that CS-5-Fu MNPs retained significant antitumor activities. Additionally, it was observed that the FITC-labeled CS-5-Fu MNPs could effectively enter into the SPCA-1 cancer cells and induced cell apoptosis...
  88. ncbi Layer-by-layer assembly of poly(L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fluorouracil
    Shifeng Yan
    Department of Polymer Materials, Shanghai University, Shanghai, China
    Eur J Pharm Biopharm 78:336-45. 2011
    ..Therefore, the novel PLGA/CS microcapsules are expected to find application in drug delivery systems because of the properties of biodegradability, high loading, sustained release and cell compatibility...
  89. ncbi Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging
    Xiaoqiang Yang
    Department of Mechanical Engineering, University of Wisconsin Milwaukee, Milwaukee, WI 53211, USA
    Biomaterials 31:9065-73. 2010
    ..These unique stable and tumor-targeting multifunctional SPIO/DOX-loaded wormlike polymer vesicles would make targeted cancer theranostics possible thereby paving the road for personalized medicine...
  90. ncbi Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior
    Yi Ping Fang
    School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan
    Eur J Pharm Biopharm 73:391-8. 2009
    ..Furthermore, the results of present study encourage more investigations on the mechanism of the interaction with ethosomes and hyperproliferative murine skin...
  91. ncbi Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles
    Shirzad Azarmi
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta, Canada T6G 2N8
    Int J Pharm 319:155-61. 2006
    ..The cell uptake of free DOX and DOX delivered by nanoparticles was confirmed using confocal laser scanning microscopy. This study supports the approach of lung cancer treatment using nanoparticles in dry powder aerosol form...
  92. ncbi Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation
    Hongliang Xin
    Department of Pharmaceutics, School of Pharmacy, Fudan University, Lane 826, Zhangheng Road, Shanghai 201203, China
    Int J Pharm 402:238-47. 2010
    ..Therefore, MPEGylated poly(ɛ-caprolactone) nanoparticles significantly enhanced the anti-glioblastoma activity of PTX and might be considered a promising drug delivery system against advanced glioblastoma...
  93. ncbi Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo
    Zhimei Song
    Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, China
    J Colloid Interface Sci 354:116-23. 2011
    ..These results suggested that PLGA-PEG-PLGA micelles would be a potential carrier for CUR...
  94. ncbi Nanoparticulate systems for brain delivery of drugs
    J Kreuter
    Institut fur Pharmazeutische Technologie, Biozentrum, J W Goethe Universitat, D 60439 Frankfurt, Germany
    Adv Drug Deliv Rev 47:65-81. 2001
    ..Other processes such as tight junction modulation or P-glycoprotein (Pgp) inhibition also may occur. Moreover, these mechanisms may run in parallel or may be cooperative thus enabling a drug delivery to the brain...
  95. ncbi Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid
    H Hatakeyama
    Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, Japan
    Gene Ther 14:68-77. 2007
    ..Thus, MEND modified with PPD is a promising device, which has the potential to make in vivo cancer gene therapy achievable...
  96. pmc Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers
    Elena V Batrakova
    Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198 5830, USA
    J Control Release 130:98-106. 2008
    ....
  97. pmc Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
    Melike Uner
    Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Beyazit 34119 Istanbul, Turkey
    Int J Nanomedicine 2:289-300. 2007
    ..The future direction of research and clinical implications of SLN is also considered...
  98. pmc Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
    Vladimir Torchilin
    Department of Pharmaceutical Sciences and Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, MA 02115, USA
    Eur J Pharm Biopharm 71:431-44. 2009
    ....
  99. ncbi Nanoparticles of biodegradable polymers for clinical administration of paclitaxel
    Si Shen Feng
    Division of Bioengineering, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
    Curr Med Chem 11:413-24. 2004
    ....
  100. ncbi Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles
    Jinghua Duan
    Key Laboratory of Nanobiological Technology, Ministry of Health National Hepatobiliary and Enteric Surgery Research Center, Central South University, Changsha, Hunan 410008, PR China
    Int J Pharm 400:211-20. 2010
    ..The curcumin nanoparticles' mechanism of action on hepatocellular carcinoma cells is a mirror that of free curcumin...
  101. pmc Development and applications of photo-triggered theranostic agents
    Prakash Rai
    Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, United States
    Adv Drug Deliv Rev 62:1094-124. 2010
    ..Specifically, we discuss recent developments in the use of theranostic agents for photodynamic-, photothermal- or photo-triggered chemotherapy for several diseases...

Research Grants64

  1. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina-Kauwe; Fiscal Year: 2012
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  2. Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
    Emmanuel O Akala; Fiscal Year: 2010
    ..targeting moieties for anti-cancer drug delivery systems, drug combination, and the development of efficient drug carriers. There is a need for the integration of all these efforts...
  3. BONE TARGETED DELIVERY OF ANABOLIC AGENTS
    JINDRICH H KOPECEK; Fiscal Year: 2011
    ..The concept of (main chain) biodegradable HPMA copolymer drug carriers targeted to bone resorption sites is a new paradigm for the design of efficient drugs for the treatment of ..
  4. Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
    Ze Lu; Fiscal Year: 2009
    ..During the Phase I SBIR grant, we evaluated several drug carriers and identified paclitaxel-loaded gelatin nanoparticles (PNP) as the candidate...
  5. Silk Fibroin Small-Molecule Drug Carriers for the Treatment of Osteoarthritis
    TIMOTHY KARIITHI MWANGI; Fiscal Year: 2013
    ..Work in Aim 1 will optimize SF modification to enable MCC coupling (SF-MCC) and synthesize two groups of drug carriers: (1) nanoparticles (<1 micron);or (2) microparticles...
  6. Nanocells for vascular normalization therapies
    Hyunjoon Kong; Fiscal Year: 2013
    ..However, the development of such multifunctional drug carriers has been plagued by difficulties in independently controlling targeting, tracking and treatment functions...
  7. Multifuctional Nanovector For Diagnosis And Treatment Of Pediatric Brain Cancer
    Miqin Zhang; Fiscal Year: 2010
    ..Our long-term objective is to develop and validate new nanoprobes serving both as imaging markers and drug carriers for non-invasive diagnosis, staging, and treatment of brain cancers...
  8. Precision engineering of ultrasonically-targeted drug delivery vehicles
    Paul A Dayton; Fiscal Year: 2012
    ..Currently, liposomes are utilized as one of the most effective drug carriers, although their in-vivo accumulation is relatively non-specific...
  9. Novel Polymeric nanoparticles for drug delivery applications
    Anthony J McGoron; Fiscal Year: 2013
    ..cisplatin, or paclitaxel) will deliver the drugs to the tumor site with a greater payload than existing drug carriers (PLGA). The quantity of drug released is governed by laser light intensity and irradiation time...
  10. Nanoparticle-mediated support of cancer immunotherapy
    Darrell J Irvine; Fiscal Year: 2013
    ..Here we propose a complementary strategy, based on the linkage of nanoparticle drug carriers (functionalized biodegradable polymer nanoparticles) to ACT T-cells, enabling T-cells to carry and release ..
  11. Microbicide Loaded Nanocarriers for Topical Delivery in HIV/AIDS Prevention
    BI BOTTI CELESTIN YOUAN; Fiscal Year: 2010
    ..The currently use of gel-based systems do not meet all these requirements. Thus nanosized drug carriers or drug loaded nanocarriers (NC) appear as promising alternative...
  12. Continuous separation of melanoma exosomes using field-flow fractionation
    Samuel A Wickline; Fiscal Year: 2013
    ..of exosomes without any labels such that these nanovesicles can be collected, modified and used as drug carriers without affecting their inherent biocompatibility and functionality...
  13. Targeting immunosuppression blockade to T cells for cancer immunotherapy
    Darrell J Irvine; Fiscal Year: 2013
    ..What is needed is a strategy to arm T-cells with nanoparticle drug carriers in vivo, directly in th blood or tissues, so that a single population of anti-tumor lymphocytes transferred ..
  14. Dynamic Microdomains in Brain Extracellular Space
    SABINA HRABETOVA; Fiscal Year: 2013
    ..basic parameter exist in living brain, yet the characteristic pore width is essential for the development of drug carriers, and for any realistic model of DMs...
  15. Lipid Nanoparticle Mediated Inhibition and Detection of Matrix Metalloproteinases
    Sanku Mallik; Fiscal Year: 2012
    ..Aside from drug carriers, the liposomal nanoparticles have potentials to form template surfaces against proteins (due to intrinsic ..
  16. Blood-Brain Barrier Disruption using Focused Ultrasound in a Large Animal Model
    Nathan J McDannold; Fiscal Year: 2010
    ..Current methods to overcome the BBB are invasive, non-targeted, and/or require the development of new drug carriers. We have shown previously that short, low-intensity focused ultrasound bursts combined with a microbubble-..
  17. Nanoparticles for targeting drug delivery to the injured vascular wall
    Kytai Nguyen; Fiscal Year: 2009
    ..on damaged ECs and vWF deposited on injured subendothelium, thereby accumulating more nanoparticles as drug carriers to the injured wall site for effective drug delivery...
  18. Long Circulating Low Molecular Weight Heparins Pulmonary
    Fakhrul Ahsan; Fiscal Year: 2006
    ..These limitations can be addressed by administering LMWHs formulated in long circulating drug carriers via the pulmonary route...
  19. Dendritic Block Copolymer Micelles as New Targeted Drug Delivery Systems
    Paula T Hammond; Fiscal Year: 2010
    ..potential clinical interest, with a focus on pharmacokinetics, biodistribution as a function of time, organ specificity, accumulation of drug carriers, intratumor uptake, and tumor inhibition as well as cytotoxicity.
  20. Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
    Mingnan Chen; Fiscal Year: 2011
    ..loaded with an anti-MIC drug, salinomycin (Sali) base on the following observations: (a) nanoscale drug carriers accumulate in the perivascular region of tumors;(b) MICs migrate through the perivascular space and invade a ..
  21. Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
    Mingnan Chen; Fiscal Year: 2013
    ..loaded with an anti-MIC drug, salinomycin (Sali) base on the following observations: (a) nanoscale drug carriers accumulate in the perivasuclar region of tumors;(b) MICs migrate through the perivascular space and invade a ..
  22. Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer
    Rasa Zarnegar; Fiscal Year: 2013
    ..Two innovative aspects in this proposal are 1) polymeric drug carriers with exceptional stability, large retention capacity of drugs, and versatility in assembly with diverse cancer ..
  23. 2012 Drug Carriers in Medicine and Biology Gordon Research Conference
    Vladimir R Muzykantov; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): We seek partial support for the Gordon Research Conference on Drug Carriers in Medicine and Biology, to be held at Waterville Valley, NH, August 12-17 in 2012...
  24. DNA-modulated release of drug from melanoma targeting NP
    Kit Lam; Fiscal Year: 2009
    ..be exploited to develop a new drug delivery paradigm by creating short anthracycline-laden dsDNA sequences as drug carriers whereby their thermal denaturation triggers the localized release of the anticancer drug...
  25. LCDIO FOR LYMPH NODE MR IMAGING
    Ralph Weissleder; Fiscal Year: 2001
    ..considerable progress in developing, characterizing and understanding the mechanism of action of lymphotropic drug carriers both for therapeutic and diagnostic purposes...
  26. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 2002
    ..5) To evaluate the in vitro antifungal activity and the in vitro/in vivo toxicity of AmB transported by micelles based PEO-b-PLAA, making comparisons with PEO-b-PLAA. ..
  27. PEG PROMOTED MUCOADHESIVE DRUG DELIVERY SYSTEMS
    NIKOLAOS PEPPAS; Fiscal Year: 1999
    DESCRIPTION: The investigators propose to develop and study the mucoadhesive behavior of hydrophilic polymer drug carriers that are modified by the addition of polyethylene glycols, as further described by their abstract: "The primary ..
  28. A Phosphorylcholine Vesicle (PCV) Platform for Cancer Therapeutics
    TODD SHANNON EMRICK; Fiscal Year: 2013
    ..offered by the phosphorylcholine (PC) groups packed along the backbone, while serving as robust cancer drug carriers for in vivo therapeutics...
  29. Poly (amino acid) as an Integrin Targeted Drug Carrier
    Xiaoling Li; Fiscal Year: 2005
    ..It is hypothesized that this interaction or specific binding can be utilized to design drug carriers for the treatment of cancer...
  30. Biocompatible Dendritic Polymers : In Vivo Applications
    FRANCIS SZOKA; Fiscal Year: 2002
    ..These novel materials can potentially be used as polymeric drug carriers, in sustained drug delivery systems or to coat implantable bioengineered medical devices...
  31. STRUCTURALLY NEW BIOPOLYMERS DERIVED FROM AMINO ACIDS
    Joachim Kohn; Fiscal Year: 1992
    ..acids) as biomaterials for a variety of medical applications such as implantable devices, injectable drug carriers, and biocompatible coatings or membranes...
  32. Transepithelial Transport of Poly Amidoamine Dendrimers
    KELLY KITCHENS; Fiscal Year: 2007
    ..this research is to develop an efficient oral drug delivery system using poly amidoamine (PAMAM) dendrimers as drug carriers. Generally, a polymeric component serves as a drug carrier in controlled drug delivery systems...
  33. CROSSLINKED LIPOSOMES AS PARTICULATE DRUG CARRIERS
    Moo Cho; Fiscal Year: 1992
    Liposomes as drug carriers have shown a wide range of therapeutic applications particularly for those disease states where macrophages are the target of pharmacological intervention...
  34. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    Glen S Kwon; Fiscal Year: 2010
    ....
  35. Nanocrystals for the Treatment of Multidrug Resistance in Cancer
    Feng Liu; Fiscal Year: 2013
    ..e., 5-fluorouracil) to synergistically kill tumor cells through different cellular mechanisms. Accomplishing these specific aims will further develop efficient nano-drug carriers for the treatment of cancer, particularly MDR cancer.
  36. ACOUSTICALLY ACTIVATED MICELLAR DRUG DELIVERY
    Natalya Y Rapoport; Fiscal Year: 2010
    ..tumor therapy using a new class of multifunctional nanoparticles that combine properties of (i) tumor-targeted drug carriers;(ii) ultrasonic drug delivery enhancers;and (iii) ultrasound contrast agents...
  37. IN VIVO IMAGING OF TUMOR CELL ENDOCYTOSIS
    Alexei Bogdanov; Fiscal Year: 2000
    ..to investigate the potential of fluid phase endocytosis (pinocytosis) as a strategy for delivering diagnostic drug carriers efficiently into tumor cells...
  38. ACOUSTICALLY ACTIVATED MICELLAR DRUG DELIVERY
    Natalya Rapoport; Fiscal Year: 2007
    ..The designed microbubbles combine four important functions: (i) drug carriers; (ii) enhancers of drug release from the carrier; enhancers of intracellular drug uptake by tumor cells; and (..
  39. Ultra High-Speed Imaging System
    Pei Zhong; Fiscal Year: 2003
    ..SWL) for the treatment of kidney stone disease, to wound healing in SWL, to the design of liposomal drug carriers, to regulation of germ line stem cell division in Drosophila, to gene therapy for cancer treatment...
  40. Peptide Ligands for Placental Transcytosis Receptors
    Giovanni Pauletti; Fiscal Year: 2006
    ..is to develop innovative delivery strategies that facilitate reproducible transfer of drugs and non-viral drug carriers across the placental barrier...
  41. Enhancing Intestinal & Brain Uptake of Anti-AIDS Drugs.
    Patrick Sinko; Fiscal Year: 2005
    ..a 30kDa bioconjugate can be taken up by and pass through intestinal and brain cell monolayers with polymeric drug carriers to overcome normal cell permeability barriers enabling enhanced bioefficacy...
  42. A NEW CLASS OF DRUG CARRIERS FOR TREATMENT OF MS
    KENNETH KOSAK; Fiscal Year: 2003
    DESCRIPTION (adapted from applicant's abstract): A patented, new class of drug carriers comprised of polymerized cyclodextrin (polyCD) will be synthesized and characterized for the treatment of MS...
  43. Micelle surface engineering for active targeting by acidic tumor extracellular pH
    You Han Bae; Fiscal Year: 2010
    ..current paradigm of active tumor targeting technology in chemotherapy is based on active internalization of drug carriers into cells by binding between a tumor specific antigen and its monoclonal antibody (mAb) or between a ligand ..
  44. MECHANISMS OF ACTION OF HIGHLY EFFICACIOUS PGA-TAXOL
    Chun Li; Fiscal Year: 2001
    ..the enhanced antitumor efficacy of PGA-taxol and aid in the future design and development of polymeric drug carriers for selective delivery of chemotherapeutic agents, it is important to investigate further the pharmacological ..
  45. Folding of Unnatural Oligomers: Hollow Helices
    Bing Gong; Fiscal Year: 2004
    ..The design of pore-forming drugs, drug carriers and sensitive membrane-bound sensors can be envisioned.
  46. Thermally-Induced Intra-Articular Drug Delivery System
    Lori Setton; Fiscal Year: 2007
    ..We further propose two specific mechanisms by which ELPs can serve as drug carriers for these protein drugs: (1) by physical entrapment of the protein drug following mixing and thermally-..
  47. INTRACELLULAR PROCESSING OF MACROMOLECULAR CONJUGATES
    Wei Chiang Shen; Fiscal Year: 1990
    ..Two non-degradable drug carriers will be used, i.e...
  48. TEMPORAL CONTROL OF DRUG DELIVERY
    William Hrushesky; Fiscal Year: 1990
    ..2 the necessity for circadian-based delivery of cancer treatments will be followed by an afternoon devoted to drug carriers, chemical-physical aspects of drug delivery and how these systems can be temporarily controlled; the morning ..
  49. Magnetomicelle Nanoparticles for Triggered Drug Delivery
    T Taton; Fiscal Year: 2006
    ..In the proposed R21 research, we will demonstrate the principle of magnetomicelle drug carriers; we hope that successful proof of principle will lead to further (R01- funded) research on the use of these ..
  50. DEVELOPMENT OF NEW LIPOPHILIC CISPLATIN ANALOGUES
    Roman Perez Soler; Fiscal Year: 1991
    ..The information generated will be essential in improving the design and use of drug carriers for antitumor agents.
  51. GORDON CONFERENCE--DRUG CARRIERS IN BIOLOGY AND MEDICINE
    COLIN GARDNER; Fiscal Year: 1990
    ..for travel and registration for speakers and session chairpersons at the 7th Gordon Research Conference on Drug Carriers in Biology and Medicine...
  52. GORDON CONFERENCE--DRUG CARRIERS IN BIOLOGY AND MEDICINE
    COLIN GARDNER; Fiscal Year: 1992
    This application is for partial funding of the Gordon Research Conference on Drug Carriers in Biology and Medicine to be held July, 1991 at The Tilton School, Tilton, New Hampshire...
  53. RESPONSIVE POLYMER ENGINEERED PROTEIN CONJUGATES
    Allan Hoffman; Fiscal Year: 2001
    ..Membrane switches are pH-responsive polymer bioconjugates or complexes with drug carriers that disrupt endosomal membranes to enhance intracellular delivery of DNA or protein drugs...
  54. DEVELOPMENT OF MODULAR NUCLEIC ACID SURROGATES
    Philip Garner; Fiscal Year: 1999
    ..If successful, this research project could lead to more effective antisense/antigene probes and/or drug carriers for use as genetically-based medicines in the treatment of viral infections and cancer.
  55. Fifth International Nanomedicine and Drug Delivery
    Vladimir Torchilin; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  56. ANTIBODY-TARGETED POLYMERIC SYSTEMS FOR TUMOR IMAGING
    Vladimir Torchilin; Fiscal Year: 2006
    ..abstract_text> ..
  57. MICELLAR CARRIERS FOR SPARINGLY SOLUBLE PHARMACEUTICALS
    Vladimir Torchilin; Fiscal Year: 2002
    We propose and study in and in vivo a new family micellar drug carriers with controlled longevity, biodistribution, and target ability...
  58. MULTIFUNCTIONAL STIMULI-SENSITIVE PHARMACEUTICAL NANOCARRIERS
    Vladimir P Torchilin; Fiscal Year: 2010
    ..So far, multiple and mainly unsuccessful attempts have been made to deliver various drug carriers (liposomes and micelles) directly into the cell cytoplasm bypassing the endocytic pathway, to protect drugs ..
  59. MICELLAR CARRIERS FOR SPARINGLY SOLUBLE PHARMACEUTICALS
    Vladimir Torchilin; Fiscal Year: 2007
    ..The development of nanoparticulate drug carriers displaying these properties for the delivery of poorly soluble pharmaceuticals still represents a challenge, ..
  60. Long-Circulating Polymer-Modified Liposomes
    Vladimir Torchilin; Fiscal Year: 2008
    ..Multiple and only partially successful attempts have been made to deliver various drugs and drug carriers (liposomes) into the cell cytoplasm to enhance the efficiency of the therapy...
  61. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007
    ..In Phase II we will develop LFn-liposomes with combination of LF and EF inhibitors, validate these liposomes in animal models of anthrax infection, and pre-clinical steps required for IND filing. [unreadable] [unreadable] [unreadable]..
  62. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer
    Marina Backer; Fiscal Year: 2008
    ..We expect that this data establish feasibility of clinical development for EGF-SLiP. [unreadable] [unreadable] [unreadable]..